Clinical guideline
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Lancet Oncol · 2025
Studies and guidelines: Endometrial (womb) cancer
8 items with a structured summary · Endometrial (womb) cancer: the complete guide
Clinical trial · Phase 3
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
N Engl J Med · 2023
74% vs 38%dMMR: 12-month progression-free survival
Clinical trial · Phase 3
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
N Engl J Med · 2022
6.6 vs 3.8 monthsMedian progression-free survival (pMMR population)
Clinical trial · Phase 3
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Lancet Oncol · 2019
81.4% vs 76.1%5-year overall survival
Clinical trial · Phase 3
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
N Engl J Med · 2019
59% vs 58%Alive and relapse-free at 60 months
Clinical trial
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
Lancet · 2010
1.8% vs 1.6%5-year vaginal recurrence
Clinical trial · Phase 3
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
JCO · 2024
HR 0.71 (95% CI 0.57–0.89)Progression-free survival (all patients): durvalumab vs control
Clinical trial · Phase 3
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
N Engl J Med · 2023
61.4% vs 15.7%dMMR/MSI-H: 24-month progression-free survival
Nothing found.